




Figure S5. Combined treatment of the rRNA synthesis inhibitor CX-5461 with ATRA.

A. Cell viability of HL-60 treated by ATRA and CX-5461 at 0/1/3/6 days. Each treatment has three repetitions.

B. Cell proliferation rate of HL-60 treated by ATRA and CX-5461 for 6 days. Data are presented as mean $\pm$ s.d. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ (two-sided t-test).

C. Flow cytometric analysis of the frequencies of CD11b⁺ cells. Data are mean $\pm$ s.d. of triplicate samples. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ (two-sided t test)